Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$136.97 USD

136.97
2,111,504

+0.09 (0.07%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kanishka Das headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

by Kanishka Das

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Kinjel Shah headshot

Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?

by Kinjel Shah

Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.

PFE vs. NVO: Which Stock Is the Better Value Option?

by Zacks Equity Research

PFE vs. NVO: Which Stock Is the Better Value Option?

TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up

by Zacks Equity Research

TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.

Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Novo Nordisk (NVO) concluded the recent trading session at $128.05, signifying a +1.04% move from its prior day's close.

Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Market Edge Highlights: LLY and NVO

by Zacks Equity Research

LLY and NVO have been highlighted in this Market Edge article.

Tracey Ryniec headshot

Is Eli Lilly's Stock in a Bubble?

by Tracey Ryniec

Shares of Eli Lilly are up 150% over the last 2 years as investors are bullish about the new weight loss drugs. Is it too hot to handle?

Ahan Chakraborty headshot

Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?

by Ahan Chakraborty

Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.

Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Novo Nordisk (NVO) closed at $133.28, indicating a +0.08% shift from the previous trading day.

Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FVD

Sanghamitra Saha headshot

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

by Sanghamitra Saha

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

Sundeep Ganoria headshot

Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?

by Sundeep Ganoria

Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.

Sundeep Ganoria headshot

Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

by Sundeep Ganoria

Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.

Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer

by Zacks Equity Research

Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.

Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug

by Zacks Equity Research

Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.

Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

In the most recent trading session, Novo Nordisk (NVO) closed at $140.87, indicating a -0.37% shift from the previous trading day.

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as Innovation, M&A Pick Up

by Kinjel Shah

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.

Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford

by Zacks Equity Research

Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.

PFE or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PFE vs. NVO: Which Stock Is the Better Value Option?

Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study

by Zacks Equity Research

Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.

Kinjel Shah headshot

Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development

by Kinjel Shah

Eli Lilly (LLY) offers to acquire Morphic Therapeutics for $3.2 billion. Pfizer (PFE) selects a once-daily formulation of danuglipron for further development as a weight loss pill.

Ahan Chakraborty headshot

Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?

by Ahan Chakraborty

Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.

Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec

by Zacks Equity Research

Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.